As the evidence for prescribing adjuvant trastuzumab is the strongest for high-risk cancers,4,6,10,11 not all early breast cancers underwent HER2 testing when trastuzumab was first introduced,21 and not all HER2-positive early breast cancers are treated with trastuzumab.21–23. Here, ERBB2 is linked to breast cancer.